Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | S100B | P04271 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 4/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11932855 | 0.81 | ALDH1A1 (0.36) | CYP3A4TSHRPIK3CAALDH1A1TDP1 | |
| SCHEMBL441345 | 0.77 | KDM1A (0.43) | ALDH1A1KDM1AKCNH2KDM1BAXL | |
| SCHEMBL580651 | 0.77 | CYP3A4 (0.46) | CYP3A4TSHRPIK3CAALDH1A1TDP1 | |
| SCHEMBL29947309 | 0.75 | CYP3A4 (0.43) | CYP3A4TSHRPIK3CAALDH1A1TDP1 | |
| SCHEMBL239637 | 0.75 | KDM1A (0.38) | ALDH1A1KDM1AKCNH2KDM1BAXL | |
| SCHEMBL29386666 | 0.75 | KDM1A (0.38) | ALDH1A1KDM1AKCNH2KDM1BAXL | |
| SCHEMBL6648558 | 0.75 | CYP3A4 (0.43) | CYP3A4TSHRPIK3CAALDH1A1TDP1 | |
| SCHEMBL16805981 | 0.75 | CYP3A4 (0.43) | CYP3A4TSHRPIK3CAALDH1A1TDP1 | |
| SCHEMBL584965 | 0.75 | KDM1A (0.33) | ALDH1A1KDM1AKCNH2KDM1B | |
| SCHEMBL29636024 | 0.75 | KDM1A (0.33) | ALDH1A1KDM1AKCNH2KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2026-04-23 | — | — | US | disclosed |
| EP-4665730-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250282746-A1 | HALOGEN-SUBSTITUTED ISOINDOLINE COMPOUND AND USE THEREOF | Chengdu Fendi Pharmaceutical Co., Ltd. (CN) | 2025-09-11 | — | — | US | disclosed |
| EP-4594324-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2025-08-06 | — | — | EP | disclosed |
| US-12365682-B2 | Process to make GLP1 RA and intermediates therefor | ELI LILLY AND COMPANY (US) | 2025-07-22 | — | — | US | disclosed |
| CN-120247804-A | Preparation method of 5-bromo-4-fluoro-1-methylindazole | 杭州国瑞生物科技有限公司 | 2025-07-04 | — | — | CN | disclosed |
| CN-120129683-A | Azole derivatives as SHP2 inhibitors | IRBM股份公司 | 2025-06-10 | — | — | CN | disclosed |
| WO-2025098515-A1 | HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2025-05-15 | — | — | WO | disclosed |
| US-12291529-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| WO-2025059577-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| US-8110578-B2 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-02-07 | — | — | US | disclosed |
| WO-2011137219-A1 | INHIBITORS OF PHOSPHOINOSITIDE DEPENDENT KINASE 1 (PDK1) | SCHERING CORPORATION (US) | 2011-11-03 | — | — | WO | disclosed |
| EP-2358718-A1 | MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY | Signal Pharmaceuticals, LLC (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-06-09 | — | — | US | disclosed |
| WO-2011053518-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-05-05 | — | — | WO | disclosed |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC | 2010-08-26 | — | — | US | disclosed |
| WO-2010062571-A1 | MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-06-03 | — | — | WO | disclosed |
| EP-0411199-B1 | Imino [(3-halogenophenyl)amino] acetic acid derivatives and herbicides containing same | SDS BIOTECH CORP (JP) | 1994-03-30 | — | — | EP | disclosed |
| US-5006160-A | Nonphytotoxic to rice | SDS BIOTECH KABUSHIKI KAISHA (JP) | 1991-04-09 | — | — | US | disclosed |
| EP-0411199-A1 | Imino [(3-halogenophenyl)amino] acetic acid derivatives and herbicides containing same | SDS BIOTECH K.K. (JP) | 1991-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282746-A1 | HALOGEN-SUBSTITUTED ISOINDOLINE COMPOUND AND USE THEREOF | FLI1, CYP3A7, GTF2I | CYP3A4 8/4885TSHR 2221/4885PIK3CA 4364/4885 |
| US-12365682-B2 | Process to make GLP1 RA and intermediates therefor | GLP1R, GIPR, NPY4R | CYP3A4 1397/4885TSHR 253/4885PIK3CA 1058/4885 |
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | PTPN1, PTPN5, PTPN3 | CYP3A4 2873/4885TSHR 445/4885PIK3CA 243/4885 |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | CYP3A4 1316/4885TSHR 1474/4885PIK3CA 10/4885 |
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | AGER, GPR119, REL | CYP3A4 137/4885TSHR 882/4885PIK3CA 2787/4885 |
| US-12291529-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, IAPP | CYP3A4 3522/4885TSHR 118/4885PIK3CA 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.